Vakrakou et al. demonstrated that systemic activation of the NLRP3 inflammasome characterizes SS patients at high risk for lymphoma development and those with established lymphoma, along with significantly increased serum IL-18 and ASC levels. The gene discussed is IL18; the disease is synovial sarcoma.